Raymond James & Associates Purchases 133,233 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James & Associates boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 672.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 153,046 shares of the company's stock after buying an additional 133,233 shares during the quarter. Raymond James & Associates owned approximately 0.12% of Henry Schein worth $11,587,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Morgan Stanley increased its holdings in shares of Henry Schein by 143.4% during the 4th quarter. Morgan Stanley now owns 2,337,890 shares of the company's stock worth $186,727,000 after buying an additional 1,377,207 shares during the last quarter. Norges Bank bought a new position in shares of Henry Schein during the fourth quarter worth about $109,932,000. Lazard Asset Management LLC lifted its position in shares of Henry Schein by 1,303.3% during the third quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company's stock worth $92,614,000 after purchasing an additional 1,158,451 shares during the last quarter. Boston Partners raised its stake in Henry Schein by 4,975.9% during the third quarter. Boston Partners now owns 1,080,598 shares of the company's stock worth $80,229,000 after acquiring an additional 1,059,309 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in Henry Schein during the second quarter worth about $36,288,000. Hedge funds and other institutional investors own 96.62% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on HSIC. Evercore ISI raised their price target on shares of Henry Schein from $79.00 to $83.00 and gave the company an "in-line" rating in a research note on Wednesday, February 28th. Piper Sandler raised their price target on shares of Henry Schein from $78.00 to $86.00 and gave the company an "overweight" rating in a report on Monday, February 26th. Barrington Research raised their price target on shares of Henry Schein from $82.00 to $90.00 and gave the company an "outperform" rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price target on shares of Henry Schein from $82.00 to $88.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. Finally, SVB Leerink began coverage on shares of Henry Schein in a report on Monday, February 26th. They set a "market perform" rating and a $78.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Henry Schein presently has an average rating of "Hold" and an average target price of $81.09.

Insider Activity

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Henry Schein Stock Performance

NASDAQ HSIC traded down $0.37 during midday trading on Friday, hitting $72.52. The company had a trading volume of 584,911 shares, compared to its average volume of 1,135,985. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of 23.02, a P/E/G ratio of 1.82 and a beta of 0.87. The firm has a fifty day simple moving average of $75.14 and a two-hundred day simple moving average of $72.64. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $85.75.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.04). The company had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The business's revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.21 earnings per share. Equities analysts forecast that Henry Schein, Inc. will post 5.07 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.